July 12, 2007 04:20 ET

DSM establishes Biomedical Scientific Advisory Board

HEERLEN, NETHERLANDS--(Marketwire - July 12, 2007) -

Following the installation of a Corporate Scientific Advisory Board in June 2007, DSM has now decided to establish a Biomedical Scientific Advisory Board to support the company in its ambitions to become a world leader in biomedical materials. The Biomedical Scientific Advisory Board will consist of renowned opinion leaders in the sciences and clinical disciplines that DSM Biomedical focuses on.

The first appointed members include Professor Tony Mikos (Rice University, Houston, USA) who will head up the Biomedical Scientific Advisory Board. He is an expert in the synthesis, processing and application development of new biomaterials and has (co)authored over 330 publications. Furthermore Dr. Ivo Buschmann (Charité, University of Medicine, Berlin and Freiburg University, Germany), and Mr. Patrick Cahalan, BSc (Ension Inc., Pittsburgh, USA) have been appointed. Dr. Buschmann is an Assistant Professor and clinical cardiologist and an expert in cardiovascular research. He heads an international research consortium called Art.Net. which focuses on experimental and clinical research in the field of vascular biology and arteriogenesis (collateral artery growth). Mr. Patrick Cahalan is a medical device industry veteran. He has over three decades of R&D experience, particularly in medical coatings, and holds more than 40 granted and pending patents.

Together with the other members, to be appointed in due course, these experts will provide advice to DSM Biomedical on its research and development strategy and program. The advice will include an assessment of R&D programs and projects vis-à-vis scientific and technological quality, validity of hypotheses, and clinical relevance.

Steve Hartig, Vice President DSM Biomedical: "I am convinced that early validation by external thought leaders of our ideas and inventions on scientific merit and relevance will considerably increase the success rate of our biomedical innovations. We are honored that such leading experts as Tony Mikos, Patrick Cahalan and Ivo Buschmann have committed themselves to our Board."

About DSM Biomedical

To meet the upcoming needs of the medical and biotech industries, DSM Biomedical builds on the expertise and strengths of DSM in polymers, coating technology, materials science and life sciences. DSM's current biomedical portfolio includes hydrophilic coating technology for catheters, guidewires and stent delivery systems and Dyneema Purity®, a specially developed, high performance polyethylene fiber technology, which is used in medical applications where maximum strength and minimum weight are required. Furthermore DSM Biomedical is focusing on developing materials and systems around implantable devices for the musculoskeletal and vascular systems and drug delivery devices in musculoskeletal, vascular and ophthalmic application areas. For more information, visit

About DSM

DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over EUR 8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at

For more information:

DSM Corporate Communications         DSM Investor Relations
Elvira Luykx                         Dries Ausems
tel. +31 (0) 45                      tel. +31 (0) 45 5782864
5782035                              fax +31 (0) 45 5782595
fax +31 (0) 45                       e-mail

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information